A Cochrane MS Review Found Stronger Evidence for Spasticity Relief Than for Neuropathic Pain
A 2022 Cochrane review found moderate-certainty evidence that nabiximols improves patient-reported spasticity in multiple sclerosis, while evidence for substantial neuropathic-pain relief was very uncertain. One symptomatic benefit did not establish equal evidence across all outcomes.
The review assessed benefits and harms separately
Twenty-five randomized trials included 3,763 participants and multiple cannabinoid preparations. The interventions and outcome-specific evidence bases differed. A total participant count should not be assigned to every individual endpoint.
Patient-reported spasticity was not all of quality of life
The review found probable benefit for perceived spasticity and global improvement, but little to no demonstrated quality-of-life effect with low-certainty evidence. Symptom relief can matter while leaving broader functioning or well-being questions unresolved.
Discontinuation and adverse effects remained relevant
Cannabinoids could increase discontinuation and selected nervous-system or psychiatric adverse effects. Evidence on drug tolerance was very uncertain, and the trials were relatively short. A favorable symptom result therefore should not be presented as proof of long-term safety or absence of adaptation.
Interpreting the evidence
This synthesis supports an outcome-specific benefit-risk account, not one general claim that cannabinoids treat MS. It does not establish disease modification or a personal treatment decision, and the differing certainty ratings belong alongside the findings.
Related reading: interpreting cannabis tolerance claims.
Research reference
Filippini G; Minozzi S; Borrelli F; Cinquini M; Dwan K (2022). Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. The Cochrane database of systematic reviews. doi:10.1002/14651858.CD013444.pub2.
This analysis draws on the supplied review abstract.
